vs
Orion S.A.（OEC）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是Orion S.A.的1.9倍（$772.1M vs $411.7M），Revvity同比增速更快（5.9% vs -5.2%），Revvity自由现金流更多（$161.8M vs $44.2M），过去两年Revvity的营收复合增速更高（9.0% vs -9.5%）
奥里昂集团成立于1917年，总部位于芬兰埃斯波，是一家全球化运营的芬兰企业。公司面向全球市场研发、生产并销售人用与兽用药品以及药用活性成分，旗下所有生产基地及大部分研发部门均设于芬兰境内。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
OEC vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$411.7M
营收增速更快
RVTY
高出11.0%
-5.2%
自由现金流更多
RVTY
多$117.6M
$44.2M
两年增速更快
RVTY
近两年复合增速
-9.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $411.7M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | 18.9% | — |
| 营业利润率 | 4.3% | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | -5.2% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $-0.36 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收OECRVTY
| Q4 25 | $411.7M | $772.1M | ||
| Q3 25 | $450.9M | $698.9M | ||
| Q2 25 | $466.4M | $720.3M | ||
| Q1 25 | $477.7M | $664.8M | ||
| Q4 24 | $434.2M | $729.4M | ||
| Q3 24 | $463.4M | $684.0M | ||
| Q2 24 | $477.0M | $691.7M | ||
| Q1 24 | $502.9M | $649.9M |
净利润OECRVTY
| Q4 25 | — | $98.4M | ||
| Q3 25 | $-67.1M | $46.7M | ||
| Q2 25 | $9.0M | $53.9M | ||
| Q1 25 | $9.1M | $42.2M | ||
| Q4 24 | — | $94.6M | ||
| Q3 24 | $-20.2M | $94.4M | ||
| Q2 24 | $20.5M | $55.4M | ||
| Q1 24 | $26.7M | $26.0M |
毛利率OECRVTY
| Q4 25 | 18.9% | — | ||
| Q3 25 | 19.0% | 53.6% | ||
| Q2 25 | 21.1% | 54.5% | ||
| Q1 25 | 20.5% | 56.5% | ||
| Q4 24 | 20.6% | — | ||
| Q3 24 | 23.2% | 56.3% | ||
| Q2 24 | 23.0% | 55.7% | ||
| Q1 24 | 24.3% | 54.6% |
营业利润率OECRVTY
| Q4 25 | 4.3% | 14.5% | ||
| Q3 25 | -11.9% | 11.7% | ||
| Q2 25 | 6.9% | 12.6% | ||
| Q1 25 | 6.5% | 10.9% | ||
| Q4 24 | 5.4% | 16.3% | ||
| Q3 24 | -3.3% | 14.3% | ||
| Q2 24 | 8.7% | 12.4% | ||
| Q1 24 | 10.5% | 6.8% |
净利率OECRVTY
| Q4 25 | — | 12.7% | ||
| Q3 25 | -14.9% | 6.7% | ||
| Q2 25 | 1.9% | 7.5% | ||
| Q1 25 | 1.9% | 6.4% | ||
| Q4 24 | — | 13.0% | ||
| Q3 24 | -4.4% | 13.8% | ||
| Q2 24 | 4.3% | 8.0% | ||
| Q1 24 | 5.3% | 4.0% |
每股收益（稀释后）OECRVTY
| Q4 25 | $-0.36 | $0.86 | ||
| Q3 25 | $-1.20 | $0.40 | ||
| Q2 25 | $0.16 | $0.46 | ||
| Q1 25 | $0.16 | $0.35 | ||
| Q4 24 | $0.31 | $0.77 | ||
| Q3 24 | $-0.35 | $0.77 | ||
| Q2 24 | $0.35 | $0.45 | ||
| Q1 24 | $0.45 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $60.7M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $384.6M | $7.3B |
| 总资产 | $1.9B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资OECRVTY
| Q4 25 | $60.7M | $919.9M | ||
| Q3 25 | $51.3M | $931.4M | ||
| Q2 25 | $42.6M | $991.8M | ||
| Q1 25 | $37.5M | $1.1B | ||
| Q4 24 | $44.2M | $1.2B | ||
| Q3 24 | $53.2M | $1.2B | ||
| Q2 24 | $34.2M | $2.0B | ||
| Q1 24 | $43.9M | $1.7B |
股东权益OECRVTY
| Q4 25 | $384.6M | $7.3B | ||
| Q3 25 | $401.8M | $7.4B | ||
| Q2 25 | $466.5M | $7.6B | ||
| Q1 25 | $466.1M | $7.6B | ||
| Q4 24 | $474.9M | $7.7B | ||
| Q3 24 | $476.3M | $7.9B | ||
| Q2 24 | $503.9M | $7.9B | ||
| Q1 24 | $492.2M | $7.8B |
总资产OECRVTY
| Q4 25 | $1.9B | $12.2B | ||
| Q3 25 | $2.0B | $12.1B | ||
| Q2 25 | $2.0B | $12.4B | ||
| Q1 25 | $2.0B | $12.4B | ||
| Q4 24 | $1.9B | $12.4B | ||
| Q3 24 | $2.0B | $12.8B | ||
| Q2 24 | $1.9B | $13.4B | ||
| Q1 24 | $1.9B | $13.4B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $92.9M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $44.2M | $161.8M |
| 自由现金流率自由现金流/营收 | 10.7% | 21.0% |
| 资本支出强度资本支出/营收 | 11.8% | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | $54.8M | $509.4M |
8季度趋势，按日历期对齐
经营现金流OECRVTY
| Q4 25 | $92.9M | $182.0M | ||
| Q3 25 | $68.8M | $138.5M | ||
| Q2 25 | $53.7M | $134.3M | ||
| Q1 25 | $400.0K | $128.2M | ||
| Q4 24 | $94.5M | $174.2M | ||
| Q3 24 | $-30.9M | $147.9M | ||
| Q2 24 | $29.3M | $158.6M | ||
| Q1 24 | $32.4M | $147.6M |
自由现金流OECRVTY
| Q4 25 | $44.2M | $161.8M | ||
| Q3 25 | $27.9M | $120.0M | ||
| Q2 25 | $11.5M | $115.5M | ||
| Q1 25 | $-28.8M | $112.2M | ||
| Q4 24 | $23.5M | $149.8M | ||
| Q3 24 | $-78.8M | $125.6M | ||
| Q2 24 | $-25.4M | $136.6M | ||
| Q1 24 | $-700.0K | $129.7M |
自由现金流率OECRVTY
| Q4 25 | 10.7% | 21.0% | ||
| Q3 25 | 6.2% | 17.2% | ||
| Q2 25 | 2.5% | 16.0% | ||
| Q1 25 | -6.0% | 16.9% | ||
| Q4 24 | 5.4% | 20.5% | ||
| Q3 24 | -17.0% | 18.4% | ||
| Q2 24 | -5.3% | 19.7% | ||
| Q1 24 | -0.1% | 20.0% |
资本支出强度OECRVTY
| Q4 25 | 11.8% | 2.6% | ||
| Q3 25 | 9.1% | 2.6% | ||
| Q2 25 | 9.0% | 2.6% | ||
| Q1 25 | 6.1% | 2.4% | ||
| Q4 24 | 16.4% | 3.4% | ||
| Q3 24 | 10.3% | 3.3% | ||
| Q2 24 | 11.5% | 3.2% | ||
| Q1 24 | 6.6% | 2.7% |
现金转化率OECRVTY
| Q4 25 | — | 1.85× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | 5.97× | 2.49× | ||
| Q1 25 | 0.04× | 3.03× | ||
| Q4 24 | — | 1.84× | ||
| Q3 24 | — | 1.57× | ||
| Q2 24 | 1.43× | 2.87× | ||
| Q1 24 | 1.21× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
OEC
| Rubber | $272.0M | 66% |
| Specialties | $139.7M | 34% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
